Spinmeisters
Executive Summary
Spin-offs are beginning to look like an industry cure-all.
You may also be interested in...
The Resurrection of Affymax
A group of venture firms decided to buy Affymax from GSK at a bargain-basement valuation. They felt it had not merely the makings of a product company but could jumpstart the creation of a fully integrated biology/screening/chemistry drug discovery company. In effect, they bought, at a discount, a proto-Vertex that wouldn't have to wait nearly a decade to see a valuation explosion.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.